Home » FDA Approves Pralatrexate for Treatment of Peripheral T-Cell Lymphoma
FDA Approves Pralatrexate for Treatment of Peripheral T-Cell Lymphoma
The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Earth Times
Earth Times
Upcoming Events
-
07May
-
14May
-
30May